Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Nov 18, 2019
American Heart Association Scientific Sessions 2019

November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Philadelphia
Nov 25, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 Year End Results
Archived Events
Date Event Details
Nov 8 - Nov 12, 2019
The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Boston

Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B

  • Publication Number: 0696
  • Session: Hepatitis B - Therapeutics: New Agents
  • Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Edward Gane, et al.

FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)

  • Publication Number: LP4
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Man-Fung Yuen, et al.
Oct 31, 2019 11:15 AM CDT
North American Cystic Fibrosis Conference
Nashville
Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”
Oct 28, 2019 2:30 PM EDT
DIA/FDA Oligonucleotide-Based Therapeutics Conference
North Bethesda, MD
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “The emerging safety and activity of siRNA drugs using the TRIMTM platform”
Oct 18, 2019 8:00 AM EDT
Arrowhead Analyst R&D Day 2019
New York, NY
Oct 7, 2019 1:30 PM EDT
Chardan 3rd Annual Genetic Medicines Conference
New York, NY
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a fireside chat presentation with Keay Nakae, CFA, Chardan senior research analyst
Oct 4, 2019 10:05 AM EDT
2019 Cantor Global Healthcare Conference
New York, NY
Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation with Elemer Piros, Ph.D., Cantor Fitzgerald biotechnology equity research analyst
Sep 20, 2019 4:15 PM CEST
Molecular Therapies for Liver Disease in Alpha-1 Antitrypsin Deficiency
Naples, Italy
Sep 16, 2019 11:00 AM +04
Global Summit On Cardiology & Heart Diseases
Dubai, UAE
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, “Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases”
Sep 16, 2019
Developing Alpha-1 Antitrypsin Therapeutics; FDA Public Workshop
Bethesda, MD
Sep 14, 2019
Alpha-1 UK Support Group Event 2019
Daventry, Northamptonshire, UK